RE:RE:RE:RE:RE:Looks like a Dense Jungle behind Ryan - nice.CommonCentsforDollars wrote: the green dank on the floor. Nothing at all to do with the plants, open your eyes.
It is dried. I looks alright to me.
Here is something can help you if Bedrocan has good quality of bad one. But I think Bedrocan has been doing this for 13 years, the quality should be way higher than the rest.
I have googled about bedrocan product, the feedbacks are great.
I know you love TWD.V very much and I have no reason to divert your attention :). But a good company does not pump its stock before dropping a bomb. You must be desparate to kill your investors. I am not saying that TWD is not a good company, I am saying TWD may do it again.
Take a look at APH.v, I am watching it as well because the CEO looks very honest to my eyes. For a speculative stock, CEO is everything.
====== Please read this and own some Bed ======
Bedrocan Canada (TSXV: BED) is a licensed producer of medical marijuana in Canada. They are a clone of their mother company, Bedrocan BV, which was formed in the Netherlands 13 years ago and is Europe's only licensed producer and exporter of pharmaceutical medical marihuana. Bedrocan Canada sells the exact same product as their European mother. $BED CANADA has some Canadian competitors. V. BED is one of about a dozen licensed producers of medical marihuana in Canada. However, unlike it's competition Bedrocan is the only company in the world that produces standardized pharmaceutical grade medical marihuana. It produces five strains of marihuana with names like Bedropuur, Bedrolite, and Bedica. The way I see it $BED has at least 5 strategic advantages that its competitors don't: 1. Experience. CEO of Bedrocan Canada, Mark Wayne, and others involved in Bedrocan BV are so trusted by Health Canada that they acted as quasi consultants to the federal government as they drafted the existing Marihuana for Medical Purposes Regulations. Health Canada even allowed Bedrocan to import marijuana from Holland to sell to patients while V.BED completed construction on their state-of-the-art facility in Toronto. The government went a step further when they allowed Bedrocan to import live marijuana clone plants from the mother company into Canada so that the Toronto facility could guarantee that the product they produce in the very near future is 100% identical to the product sold in the Netherlands. These groundbreaking privileges were extended to no other licensed producer. 2. Reputation. Bedrocan is the only company in the world able to grow and sell standardized pharmaceutical marijuana. This means that the chemical composition of the medicine is identical from batch to batch. This also means that doctors are more apt to write prescriptions for marihuana they know will have consistent levels of the active ingredients like THC and CBD and insurance companies are more likely to cover costs associated with these prescriptions. In fact, just recently a Canadian university student became the first person in the country to have his marihuana script covered by Sun Life Insurance; not surprisingly his licensed producer was Bedrocan. 3. Product Quality. Bedrocan sells five strains of marijuana. Each stain is standardized and pharmaceutical grade. The strains are strong, well known, and professionally named. While its competitors still push their products using the street names, $BED markets medicine named Bediol, etc. 4. Customer Orientated. The traders and stock analysts seem to prefer the bigger licensed producers who seemingly hype their stock weekly with unnecessary news releases and the truth is that some of these huge licensed producers will see their stock price per share explode if and when marijuana is recreationally legalized in Canada. However these other licensed producers under the MMPR will run out of money if "weed" isn't legalized soon. On the other hand Bedrocan has a chance to survive as a company regardless of recreational legalization. They have built their company to serve medical patients and if the current trends continue V.BED is not too far away from profitability. Not only that but if and when marijuana is legalized Bedrocan's stock will skyrocket just the same as its competitor's. Bedrocan has a Patient Advisory Board led by a well known Canadian marijuana activist and seems to have the patients, governments, insurance companies, and doctors on their side. 5. Growth Potential. Bedrocan's leverage creates lots of feasible opportunities. For one thing Bedrocan is in a great position to begin exporting its product to places like the United States and South America. Its standardized pharmaceutical medical marijuana is already used in other products in Israel and seems like the obvious choice to be used by big pharmaceutical companies in any new marihuana based drugs. Moreover in the next few months a couple of precedent setting court cases will be decided by the Canadian courts. These decisions may open up the marijuana edible market to Bedrocan and also exponentially increase its customer base if the judges decide that patients must be forced to buy marihuana from licensed producers. And then of course there is the Canadian federal election in October in which marijuana legalization will certainly be on the table. These competitive advantages are the reasons why Dividendmonsters.com has decided to invest in this company. Like all of our investments this is a long term addition. V. BED is currently trading at $0.76. It is a speculative stock and with that comes great risk and reward so I suspect in 10 years it will be worth absolutely nothing or 100X its current value. Either way I hope to be retired, living on dividends, and sitting on my deck sipping on a whiskey (and perhaps puffing on some Bedropuur). Do your own research and come to your own conclusions but Bedrocan might be worth taking a chance on.